NeuroOne Medical Technologies
NMTC
18 hedge funds and large institutions have $2.19M invested in NeuroOne Medical Technologies in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 4 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
0% more funds holding
Funds holding: 18 → 18 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0.19% less ownership
Funds ownership: 1.83% → 1.64% (-0.19%)
36% less capital invested
Capital invested by funds: $3.42M → $2.19M (-$1.23M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$59.9K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$38.7K |
| 3 |
VF
Virtu Financial
New York
|
+$20.1K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$18.2K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$10.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$260K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$13.6K |
| 3 |
CA
Centerpoint Advisors
Needham,
Massachusetts
|
-$6K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$1.8K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$232 |
NMTC Hedge Fund Activity: Q2 2024 in Review
18 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in NeuroOne Medical Technologies (NMTC) for Q2 2024, worth a combined $2.19M — down 36% from $3.42M a quarter earlier.
Fund positioning in NMTC was balanced in Q2 2024: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, adding an estimated $59.9K. The largest seller was Nantahala Capital Management, cutting an estimated $260K.
- 18 institutional investors held NeuroOne Medical Technologies (NMTC) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $2.19M of NeuroOne Medical Technologies stock for Q2 2024, down 36% quarter-over-quarter.
- 4 funds opened new NeuroOne Medical Technologies positions in Q2 2024 and 4 closed out, a net change of 0 holders.
- The largest NeuroOne Medical Technologies buyer in Q2 2024 was UBS Group, an estimated $59.9K added.
- The largest NeuroOne Medical Technologies seller in Q2 2024 was Nantahala Capital Management, an estimated $260K sold.
Based on aggregated 13F filings for Q2 2024.